Chronic exposure to methylphenidate impairs appendicular bone quality in young rats

Bone

Volumn 50, Issue 6, 2012, Pages 1214-1222

  Komatsu, David E ^a   Thanos, Panayotis K ^b,c   Mary, Michelle N ^d   Janda, Haden A ^e   John, Christine M ^e   Robison, Lisa ^b   Ananth, Mala ^b   Swanson, James M ^f   Volkow, Nora D ^c   Hadjiargyrou, Michael ^g  

^a STONY BROOK UNIVERSITY   (United States)

^b BROOKHAVEN NATIONAL LABORATORY   (United States)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e InMotion Orthopaedic Research Center   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g St Francis Hospital The Heart Center   (United States)

Author keywords

Biomechanics; DXA; Growth suppression; Methylphenidate; Testosterone

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN; DRINKING WATER; METHYLPHENIDATE; TESTOSTERONE;

ADOLESCENT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; BIOMECHANICS; BODY WEIGHT; BONE DENSITOMETRY; BONE DENSITY; BONE MINERAL; BONE QUALITY; CONTROLLED STUDY; DRUG EXPOSURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR; FOOD INTAKE; FORCE; LUMBAR VERTEBRA; MALE; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; RAT; TIBIA;

ADOLESCENT; ALKALINE PHOSPHATASE; ANIMALS; BIOLOGICAL MARKERS; BIOMECHANICS; BONE AND BONES; BONE DENSITY; BONE DEVELOPMENT; CENTRAL NERVOUS SYSTEM STIMULANTS; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; METHYLPHENIDATE; MODELS, ANIMAL; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RISK FACTORS; TESTOSTERONE; TIME FACTORS;

EID: 84859627956     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.03.011     Document Type: Article

References (29)

1. Dopheide J.A., Pliszka S.R. Attention deficit hyperactivity disorder: an update. Pharmacotherapy 2009, 29:656-679.
2. Loe I.M., Feldman H.M. Academic and educational outcomes of children with ADHD. J Pediatr Psychol 2007, 32:643-654.
3. Edwards G., Barkley R.A., Laneri M., Fletcher K., Metevia L. Parent-adolescent conflict in teenagers with ADHD and ODD. J Abnorm Child Psychol 2001, 29:557-572.
4. Konofal E., Lecendreux M., Cortese S. Sleep and ADHD. Sleep Med 2010, 11:652-658.
5. Mannuzza S., Klein R.G., Moulton J.L. Lifetime criminality among boys with attention deficit hyperactivity disorder: a prospective follow-up study into adulthood using official arrest records. Psychiatry Res 2008, 160:237-246.
6. James A., Lai F.H., Dahl C. Attention deficit hyperactivity disorder and suicide: a review of possible associations. Acta Psychiatr Scand 2004, 110:408-415.
7. Weber W., Newmark S. Complementary and alternative medical therapies for attention-deficit/hyperactivity disorder and autism. Pediatr Clin North Am 2007, 54:983-1006.
8. Knight L.A., Rooney M., Chronis-Tuscano A. Psychosocial treatments for attention-deficit/hyperactivity disorder. Curr Psychiatry Rep 2008, 10:412-418.
9. MTA Cooperative Group A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999, 56:1073-1086.
10. Biederman J., Faraone S.V. Attention-deficit hyperactivity disorder. Lancet 2005, 366:237-248.
11. Goldman L.S., Genel M., Bezman R.J., Slanetz P.J. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Am Med Assoc 1998, 279:1100-1107.
12. Swanson J.M., Elliott G.R., Greenhill L.L., Wigal T., Arnold L.E., Vitiello B., et al. Effects of stimulant medication on growth rates across 3years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 2007, 46:1015-1027.
13. Safer D., Allen R., Barr E. Depression of growth in hyperactive children on stimulant drugs. N Engl J Med 1972, 287:217-220.
14. MTA Cooperative Group National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 2004, 113:762-769.
15. Swanson J., Greenhill L., Wigal T., Kollins S., Stehli A., Davies M., et al. Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry 2006, 45:1304-1313.
16. Pliszka S.R., Matthews T.L., Braslow K.J., Watson M.A. Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006, 45:520-526.
17. Kramer J.R., Loney J., Ponto L.B., Roberts M.A., Grossman S. Predictors of adult height and weight in boys treated with methylphenidate for childhood behavior problems. J Am Acad Child Adolesc Psychiatry 2000, 39:517-524.
18. Greeley G.H., Kizer J.S. The effects of chronic methylphenidate treatment on growth and endocrine function in the developing rat. J Pharmacol Exp Ther 1980, 215:545-551.
19. Pizzi W.J., Rode E.C., Barnhart J.E. Methylphenidate and growth: demonstration of a growth impairment and a growth-rebound phenomenon. Dev Pharmacol Ther 1986, 9:361-368.
20. Pizzi W.J., Rode E.C., Barnhart J.E. Differential effects of methylphenidate on the growth of neonatal and adolescent rats. Neurotoxicol Teratol 1987, 9:107-111.
21. Malitsis N., Wang G.J., Swanson J.M., Volkow N.D., Thanos P.K. Chronic oral methylphenidate exposure during adolescence: effects on open field locomotor activity, novel object recognition and circadian activity. Annual meetings of Society for Neuroscience 2008, 59:6DD12.
22. Warden S.J., Komatsu D.E., Rydberg J., Bond J.L., Hassett S.M. Recombinant human parathyroid hormone (PTH 1-34) and low-intensity pulsed ultrasound have contrasting additive effects during fracture healing. Bone 2009, 44:485-494.
23. Komatsu D.E., Mary M.N., Schroeder R.J., Robling A.G., Turner C.H., Warden S.J. Modulation of Wnt signaling influences fracture repair. J Orthop Res 2010, 28:928-936.
24. Cullinane D.M. Axial versus appendicular: constraint versus selection. Am Zool 2000, 40:136-145.
25. Francis R.M. The effects of testosterone on osteoporosis in men. Clin Endocrinol (Oxf) 1999, 50:411-414.
26. Hibel L.C., Granger D.A., Cicchetti D., Rogosch F. Salivary biomarker levels and diurnal variation: associations with medications prescribed to control children's problem behavior. Child Dev 2007, 78:927-937.
27. Poulton A. Growth on stimulant medication; clarifying the confusion: a review. Arch Dis Child 2005, 90:801-806.
28. Bliziotes M., McLoughlin S., Gunness M., Fumagalli F., Jones S.R., Caron M.G. Bone histomorphometric and biomechanical abnormalities in mice homozygous for deletion of the dopamine transporter gene. Bone 2000, 26:15-19.
29. Safer D.J., Allen R.P., Barr E. Growth rebound after termination of stimulant drugs. J Pediatr 1975, 86:113-116.